Progress in Pediatric Cardiology
Volume 23, Issue 1 , Pages 5-15 , September 2007

Classification of the cardiomyopathies

  • Steven D. Colan

      Affiliations

    • Corresponding Author InformationDepartment of Cardiology, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States. Tel.: +1 6173557893; fax: +1 6177396282.

References 

  1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816
  2. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–842
  3. Abelmann WH. Classification and natural history of primary myocardial disease. Prog Cardiovasc Dis. 1984;27:73–94
  4. Report of the WHO/ISFC . Task Force on the definition and classification of cardiomyopathies. Br Heart J. 1980;44:672–673
  5. Boffa GM, Thiene G, Nava A, Dalla Volta S. Cardiomyopathy: a necessary revision of the WHO classification. Int J Cardiol. 1991;30:1–7
  6. Keren A, Popp RL. Assignment of patients into the classification of cardiomyopathies. Circulation. 1992;86:1622–1633
  7. Franklin RC. The European paediatric cardiac code long list: structure and function. Cardiol Young. 2000;10(Suppl 1):27–146
  8. Delius RE. Congenital heart surgery and database project: pediatric cardiomyopathies and end-stage congenital heart disease. Ann Thorac Surg. 2000;69:S180–S190
  9. Schwartz ML, Cox GF, Lin AE, et al. Clinical approach to genetic cardiomyopathy in children. Circulation. 1996;94:2021–2038
  10. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865–872
  11. Thiene G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification?. Eur Heart J. 2004;25:1772–1775
  12. Thiene G, Angelini A, Basso C, Calabrese F, Valente M. The new definition and classification of cardiomyopathies. Adv Clin Path. 2000;4:53–57
  13. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115:773–781
  14. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–1114
  15. Woo A, Rakowski H, Liew JC, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart. 2003;89:1179–1185
  16. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics. 1978;61:100–107
  17. Anan R, Nakagawa M, Miyata M, et al. Cardiac involvement in mitochondrial diseases: a study on 17 patients with documented mitochondrial DNA defects. Circulation. 1995;91:955–961
  18. Finsterer J, Stollberger C, Schubert B. Acquired left ventricular hypertrabeculation/noncompaction in mitochondriopathy. Cardiology. 2004;102:228–230
  19. Rigopoulos A, Rizos IK, Aggeli C, et al. Isolated left ventricular noncompaction: an unclassified cardiomyopathy with severe prognosis in adults. Cardiology. 2002;98:25–32
  20. Oechslin EN, Jost CHA, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000;36:493–500
  21. Stollberger C, Winkler-Dworak M, Blazek G, Finsterer J. Left ventricular hypertrabeculation/noncompaction with and without neuromuscular disorders. Int J Cardiol. 2004;97:89–92
  22. Finsterer J, Stollberger C, Kopsa W. Familial left ventricular hypertrabeculation in myotonic dystrophy type 1. Herz. 2003;28:466–470
  23. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics. 2004;114:925–931
  24. Chen R, Tsuji T, Ichida F, et al. Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. Mol Genet Metab. 2002;77:319–325
  25. McMahon CJ, Chang AC, Pignatelli RH, et al. Left Ventricular Noncompaction Cardiomyopathy in Association with Trisomy 13. Pediatr Cardiol. 2005;26(4):477–479
  26. Stollberger C, Finsterer J, Voigtlander T, Slany J. Is left ventricular hypertrabeculation/noncompaction a cardiac manifestation of Fabry's disease?. Z Kardiol. 2003;92:966–969
  27. Stollberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr. 2004;17:91–100
  28. Kenton AB, Sanchez X, Coveler KJ, et al. Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12. Mol Genet Metab. 2004;82:162–166
  29. Varvava AM. Isolated left ventricular non-compaction: a distinct cardiomyopathy?. Heart. 2001;86:599–600

☆ Supported by NIH NHLBI grant RO1 HL53392 and the Children's Cardiomyopathy Foundation, Inc.

PII: S1058-9813(07)00004-5

doi: 10.1016/j.ppedcard.2007.05.003

Progress in Pediatric Cardiology
Volume 23, Issue 1 , Pages 5-15 , September 2007

Article Tools